General Atlantic

Immunocore Limited is a biotechnology company based in Abingdon, United Kingdom, with a focus on discovering and developing novel therapeutics for cancer, viral diseases, and autoimmune conditions. The company specializes in T cell receptor (TCR) technology, which allows it to create innovative bispecific immunotherapies. Its lead product candidate, IMCgp100, is currently undergoing clinical trials for the treatment of metastatic melanoma. Immunocore's proprietary platform enables efficient manufacturing of TCR-based drugs, addressing significant unmet medical needs. Founded in 1999 and previously known as Avidex Limited, Immunocore has expanded its operations with an additional office in Conshohocken.

Duolingo, Inc. is a language-learning platform founded in 2011 and headquartered in Pittsburgh, Pennsylvania. The company offers a free service that enables users to learn nearly 40 languages through 98 distinct courses, with an option for a premium subscription that provides additional features such as ad removal and offline access. Duolingo claims to have 30 million active users, making it a leading educational app globally. It also provides tailored solutions for educators through "Duolingo for Schools," which allows teachers to monitor student progress. The platform utilizes advanced data analytics and artificial intelligence to enhance the learning experience, incorporating engaging design elements to keep users motivated. Duolingo's revenue primarily derives from subscriptions, and it has emerged as a top-grossing app in the education category on both Google Play and the Apple App Store.

Duolingo, Inc. is a language-learning platform founded in 2011 and headquartered in Pittsburgh, Pennsylvania. The company offers a free service that enables users to learn nearly 40 languages through 98 distinct courses, with an option for a premium subscription that provides additional features such as ad removal and offline access. Duolingo claims to have 30 million active users, making it a leading educational app globally. It also provides tailored solutions for educators through "Duolingo for Schools," which allows teachers to monitor student progress. The platform utilizes advanced data analytics and artificial intelligence to enhance the learning experience, incorporating engaging design elements to keep users motivated. Duolingo's revenue primarily derives from subscriptions, and it has emerged as a top-grossing app in the education category on both Google Play and the Apple App Store.

Immunocore Limited is a biotechnology company based in Abingdon, United Kingdom, with a focus on discovering and developing novel therapeutics for cancer, viral diseases, and autoimmune conditions. The company specializes in T cell receptor (TCR) technology, which allows it to create innovative bispecific immunotherapies. Its lead product candidate, IMCgp100, is currently undergoing clinical trials for the treatment of metastatic melanoma. Immunocore's proprietary platform enables efficient manufacturing of TCR-based drugs, addressing significant unmet medical needs. Founded in 1999 and previously known as Avidex Limited, Immunocore has expanded its operations with an additional office in Conshohocken.